Last Updated : May 9, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort ascending | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Lixiana VTE | Edoxaban | Venous thromboembolism, treatment and recurrence prevention. | Reimburse with clinical criteria and/or conditions | Complete | ||
Fentora | Fentanyl buccal | Pain (breakthrough), cancer (adults) | Do not reimburse | Complete | ||
Ibrance Resubmission | Palbociclib | Advanced breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Cortiment | Budesonide | Ulcerative Colitis | Do not reimburse | Complete | ||
Afinitor | Everolimus | Neuroendocrine tumors (NET) of Gastrointestinal or Lung origin | Reimburse with clinical criteria and/or conditions | Complete | ||
Quinsair | Levofloxacin | Cystic fibrosis with chronic pulmonary Pseudomonas aeruginosa infections | Reimburse with clinical criteria and/or conditions | Complete | ||
Cinqair | Reslizumab | Asthma, eosinophilic | Reimburse with clinical criteria and/or conditions | Complete | ||
Uptravi | Selexipag | Pulmonary arterial hypertension (WHO class II and III) | Reimburse with clinical criteria and/or conditions | Complete | ||
Taltz | Ixekizumab | Psoriasis, moderate to severe plaque | Reimburse with clinical criteria and/or conditions | Complete | ||
Lynparza | Olaparib | Ovarian Cancer | Do not reimburse | Complete |